Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
2(15%)
Results Posted
50%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
1
8%
Ph phase_4
4
31%
Ph not_applicable
1
8%
Ph phase_3
5
38%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

1

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
5(41.7%)
Phase 4Post-market surveillance
4(33.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(8)
Terminated(3)

Detailed Status

Completed8
Recruiting2
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 21 (8.3%)
Phase 35 (41.7%)
Phase 44 (33.3%)
N/A1 (8.3%)

Trials by Status

recruiting215%
terminated18%
completed862%
withdrawn215%

Recent Activity

2 active trials
Showing 5 of 13
recruitingphase_2

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319
recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
completedphase_4

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma

NCT00830505
terminatedphase_4

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

NCT02491970
completednot_applicable

Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

NCT01231230
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06676319Phase 2

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Recruiting
NCT00576069

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting
NCT00830505Phase 4

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma

Completed
NCT02491970Phase 4

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

Terminated
NCT01231230Not Applicable

Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

Completed
NCT01709903Phase 3

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Completed
NCT00530842Phase 4

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Completed
NCT01860066Phase 3

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Withdrawn
NCT01834885Phase 3

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Withdrawn
NCT01315249Phase 3

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00646009Phase 3

Symbicort Onset of Action 2

Completed
NCT01186653Phase 4

Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00908362Phase 1

Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13